So different and the same probiotics -the problem of choice


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents various definitions of probiotics. Microorganisms that are included as a compound of probiotics are described. An assessment of the domestic and global market for probiotic preparations is given. The properties of individual probiotic strains, features of technological production and evaluation of the probiotic quality, specific recommendations for different indications for taking probiotics based on evidence levels are discussed. The significance of probiotics in nutrition, their mechanisms of action are demonstrated. A new probiotic, Lactobalance, is presented.

Full Text

Restricted Access

About the authors

Ekaterina Yu. Plotnikova

Kemerovo State Medical University

Email: eka-pl@rambler.ru
MD, Professor at the Department of Primary Health Care Doctors Training, Head of Course of Clinical Gastroenterology

V. B Grinevich

S.M. Kirov Military Medical Academy

Yu. V Zakharova

Kemerovo State Medical University

T. Yu Gracheva

Kemerovo State Medical University

References

  1. Isolauri E. Probiotics in human disease. Am J. Clin Nutr. 1973;114:2-6.
  2. Sanderson I.R., Walker W.A. Uptake and transport of macromolecules by the intestine: possible role in clinical disorders (an update). Gastroenterology. 1993;104:622-39.
  3. Carol M., Lambrechts A., Van Gossum A., et al. Spontaneous secretion of interferon-Y and leukin 4 by human intraepithelial and lamina propria gut lymphocytes. Gut. 1998;42:643-49.
  4. Bengmark S. Ecological control of the gastrointestinal tract: the role of probiotic flora. Gut. 1998;42:2-7.
  5. Soutar A., Seaton A., Brown K. Bronchial reactivity and dietary antioxidants. Thorax. 1997;52:166-70.
  6. Sütas Y., Soppi E., Korhonen H., et al. Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolysed with Lactobacillus GG-derived enzymes. J. Allergy Clin Immunol. 1996; 98:216-24.
  7. Pessi T., Sütas Y., Saxelin M., et al. Antiproliferative effects of homogenates derived from five strains of candidate probiotic bacteria. Appl Environ Microbiol. 1999;65:4725-28.
  8. Salmine S., Isolauri E., Salmine E. Clinical use of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. Antonie Van Leeuwenhoek. 1996;70:347-45.
  9. Food and Agricultural Organization of the United Nations and World Health Organization. Joint FAO/WHO working group report on drafting guidelines for the evaluation of probiotics in food. 2002. URL: http://www. un.org/youthenvoy/2013/09/fao-food-and-agriculture-organization-of-the-united-nations/
  10. Hill C., Guarner F., Reid G., et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-14. doi: 10.1038/nrgastro.2014.66.
  11. ГОСТ Р. 52349-2005 «Продукты пищевые. Продукты пищевые функциональные. Термины и определения». М.: Стандартинформ, 2015.17 с.
  12. URL: https://www.euromonitor.com/
  13. Lynch S.V., Pedersen O. The human intestinal microbiome in health and disease. N. Engl J. Med. 2016;375:2369-79.
  14. Haelle T. Two Studies May Change View of Probiotics: One Size May Not Fit All - Medscape. 2018. URL: https://www.medscape.com/ viewarticle/903419#vp_1
  15. McFarland L.V. Meta-Analysis of Probiotics for the prevention of Antibiotic Associated Diarrhea and the Treatment of Clostridium difficile Disease. Am J. Gastroenterol. 2006;101:812-22.
  16. Sazawal S., Hiremath G., Dhingra U., et al. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 2006;6: 374-82.
  17. Tong J.L., Ran Z.H., Shen J., et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155-68.
  18. McFarland L.V., Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol. 2008;14(17):2650-61.
  19. Hoveyda N., Heneghan C., Mahtani K.R., et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterology. 2009;9:15. doi: 10.1186/1471-230X-9-15.
  20. Levels of Evidence, Oxford Centre for Evidence-Based Medicine. 2011. URL: http://www.cebm. net/index.aspx?o=5653.
  21. Guarner F., Khan A.G., Garisch J., et al. Всемирная гастроэнтерологическая организация. Практические рекомендаци. Пробиотики и пребиотики. [World Gastroenterological Organization. Practical recommendations. Probiotics and prebiotics.] URL: http://www. worldgastroenterology.org/guidelines/globalguidelines/probiotics-and-prebiotics/probioticsand-prebiotics-russian
  22. Doron S., Snydman D.R. Risk and safety of probiotics. Clin Infect Dis. 2015;60 (2):129-34. doi: 10.1093/cid/civ085.
  23. Fijan S. Microorganisms with claimed probiotic properties: an overview of recent literature. Int J. Environ Res Public Health. 2014;11:4745-67. doi: 10.3390/ijerph110504745.
  24. Hemarajata P., Versalovic J. Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therap Adv Gastroenterol. 2013;6:39-51. doi: 10.1177/1756283X12459294.
  25. Khailova L., Petrie B., Baird C.H., et al. Lactobacillus rhamnosus GG and Bifidobacterium longum attenuate lung injury and inflammatory response in experimental sepsis. PLoS One. 2014;9:e97861. doi: 10.1371/journal. pone.0097861.
  26. Tham C.S., Peh K.K., Bhat R., Liong M.T. Probiotic properties of bifidobacteria and lactobacilli isolated from local dairy products. Ann Microbiol. 2012;62:1079-87.
  27. Sarkar A., Mandal S. Bifidobacteria-Insight into clinical outcomes and mechanisms of its probiotic action. Microbiol Res. 2016;192:159-71. doi: 10.1016/j.micres.2016.07.001.
  28. Drago L., De Vecchi E., Gabrieli A., et al. Immunomodulatory Effects of Lactobacillus salivarius LS01 and Bifidobacterium breve BR03, Alone and in Combination, on Peripheral Blood Mononuclear Cells of Allergic Asthmatics. Allergy Asthma Immunol Res. 2015;7:409-13. doi: 10.4168/aair.2015.7.4.409.
  29. Inturri R., Stivala A., Blandino G. Microbiological characteristics of the probiotic strains B. longum BB536 and L. rhamnosus HN001 used in combination. Minerva Gastroenterol Dietol. 2015;61:191-97.
  30. Inturri R., Stivala A., Furneri P.M., Blandino G. Growth and adhesion to HT-29 cells inhibition of Gram-negatives by Bifidobacterium longum BB536 e Lactobacillus rhamnosus HN001 alone and in combination. Eur Rev Med Pharmacol Sci. 2016;20:4943-49.
  31. Wickens K., Stanley T.V., Mitchell E.A., et al. Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization? Clin Exp Allergy. 2013;43:1048-57. Doi: 10.1111/ cea.12154.
  32. Al-Sheraji S.H., Amin I., Azlan A., et al. Effects of Bifidobacterium longum BB536 on lipid profile and histopathological changes in hypercholesterolaemic rats. Benef Microbes. 2015;6:661-68. doi: 10.3920/BM2014.0032.
  33. Akatsu H., Iwabuchi N., Xiao J.Z., et al. Clinical effects of probiotic Bifidobacterium longum BB536 on immune function and intestinal microbiota in elderly patients receiving enteral tube feeding. JPEN J. Parenter Enteral Nutr. 2013;37:631-40. doi: 10.1177/0148607112467819.
  34. Odamaki T., Sugahara H., Yonezawa S., et al. Effect of the oral intake of yogurt containing Bifidobacterium longum BB536 on the cell numbers of enterotoxigenic Bacteroides fragilis in microbiota. Anaerobe. 2012;18:14-18. doi: 10.1016/j.anaerobe.2011.11.004.
  35. МУ 2.3.2.2789-10 «Методические указания по санитарно-эпидемиологической оценке безопасности и функционального потенциала пробиотических микроорганизмов, используемых для производства пищевых продуктов». М., 2011. 105 с/MI 2.3.2.2789-10 "Methodical instructions for the sanitary-epidemiological assessment of the safety and functional potential of probiotic microorganisms used for the production of food products". Moscow, 2011. 105 p. (In Russ.)].
  36. Определение специфической активности пробиотиков: ОФС 1.7.2.0009-15: Общая фармакопейная статья. М., 2015. 24 с.
  37. Whitman W.B., Goodfellow M., Kämpfer P., et al. Bergey's Manual of Systematic Bacteriology: 2nd ed. New York: Springer-Verlag. 2012;5(parts A and B). 2031 p.
  38. Esaiassen E., Hjerde E., Cavanagh J.P. et al. Bifidobacterium bacteremia: clinical characteristics and a genomic approach to assess pathogenicity. J. Clin Microbiol. 2017;55(7):2234-48. Doi: 10.1128/ JCM.00150-17.
  39. Ohishi A., Takahashi Sh., Ito Y. et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. The Journal of Pediatrics. 2010; 156:679-81. Doi: 10.101 6/j. jpeds.2009.11.041.
  40. Глушанова, Н.А. Влияние пробиотиков на индигенную микрофлору здорового организма. Сибирский медицинский журнал. 2004;3:65-71.
  41. Плотникова Е.Ю., Захарова Ю.В. Место пробиотиков в современной клинической практике. Consilium medicum. Педиатрия. 2018;1:30-34.
  42. Honma N. On effects of lactic acid bacteria. Part I. Biological significance. New Med Clin. 1986;35:2687-95.
  43. Honma N, Ohtani K., Kikuchi H. On effects of lactic acid bacteria. Part II. Clinical effects. New Medicines and Clinics. 1987;36(1):75.
  44. Willard T. Kyo-Dophilus use in the reduction of Candida albicans symptoms. Calgary. Canada. Chiron Consultants. 1989. Поступила / Received: 18.01.2019 Принята в печать/Accepted: 15.02.2019

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media